Invera Wealth Advisors LLC Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Invera Wealth Advisors LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,098 shares of the medical research company’s stock after buying an additional 102 shares during the period. IQVIA accounts for about 2.9% of Invera Wealth Advisors LLC’s holdings, making the stock its 14th largest holding. Invera Wealth Advisors LLC’s holdings in IQVIA were worth $2,904,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of IQV. Capital Performance Advisors LLP acquired a new position in IQVIA in the 3rd quarter valued at about $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, Concord Wealth Partners purchased a new position in shares of IQVIA during the 3rd quarter worth $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

NYSE IQV opened at $196.54 on Thursday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $34.61 billion, a PE ratio of 26.21, a P/E/G ratio of 1.98 and a beta of 1.48. The company’s 50 day simple moving average is $199.95 and its 200 day simple moving average is $217.09.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IQV. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Leerink Partners restated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays lowered their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $251.22.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.